Skip to main content
Fig. 1 | BMC Infectious Diseases

Fig. 1

From: An open label, randomised controlled trial of rifapentine versus rifampicin based short course regimens for the treatment of latent tuberculosis in England: the HALT LTBI pilot study

Fig. 1

Flow diagram of recruitment of individuals to trial, allocation, and outcomes. a: Individuals with latent tuberculosis infection (LTBI) were recruited from TB clinics who agreed to treatment and met the eligibility criteria. b: Subjects randomised to weekly rifapentine/isoniazid (3HP) or daily rifampicin/isoniazid (3HR). c: Follow-up at 2, 4, 8, 12 weeks. d: Treatment completion defined as more than 90% of prescribed doses taken post treatment completion one subject was LFU and another an investigator withdrawal. ** n (%) individuals, per arm, that experienced any AE likely due to drug, as per investigator decision

Back to article page